drugset
drugset / Trial / NCT03457844

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

NCT03457844 ↗

Phase 2 Unknown 60 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3.

Timeline

Start
2018-01-30
Primary completion
2019-08-30
Completion
2019-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule — —

Indications

carcinoid tumor